Human CD59, Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-Human CD59, antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Human CD59, |
| Clone | [1F5] |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | fluorescein (FITC) conjugate |
| Size | 0.1 mg |
| Concentration | 0.1 mg/ml |
| Applications | Immunohistochemistry (IHC) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: CD59 (Protectin) (Human CD59). CD59 (also known as HRF20, protectin) is a 20 kDa glycoprotein attached to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It blocks MAC formation in the complement pathway by interfering with C9 membrane insertion and polymerization, but it does not affect the generation of C3 and C5 activation products. CD59 is expressed on several cell types, including leukocytes, endothelial and epithelial cells, erythrocytes, and cells of the central nervous system. CD59 belongs to the Ly6 superfamily of proteins. This product is suitable for use in flow cytometry. |
| Immunogen | Immunogen: Mouse pre-B tumour cells (RAW112). Donor: Lewis rat spleen. Fusion Partner: S 194/5. XXO. BU-1 |
| Other Names | [CD59, (FITC) (Clone 1F5) (mouse IgG1); Human CD59], [CD59; CD59; 1F5; EJ16; EJ30; EL32; G344; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; 16.3A5; HRF-20; MAC-IP; p18-20; MIC11; MIN1; MIN2; MIN3; MSK21; HRF-20; HRF20; MAC-IP; MACIF; MIRL] |
| Gene, Accession # | [CD59], Gene ID: 966, NCBI: NP_976076.1, UniProt: P13987 |
| Catalog # | MBS520190 |
| Price | $255 |
| Order / More Info | Human CD59, Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies